DOJ’s 2026 National Health Care Fraud Takedown: 455 Charged, $6.5B Alleged Fraud
The U.S. Department of Justice announced results of its 2026 National Health Care Fraud Takedown on June 23, 2026, saying federal prosecutors have charged 455 defendants (including 90 doctors and other licensed medical professionals) in connection with schemes involving over $6.5 billion in alleged false claims and significant patient harm, including death. The case activity is spread across 56 federal districts and 45 states and territories, DOJ said.
What DOJ says was involved
DOJ described the charged conduct as health care fraud and alleged opioid abuse schemes. According to the announcement, prosecutors are pursuing accountability for alleged wrongdoing across a range of roles, from clinical settings to corporate leadership positions.
As DOJ explains, the allegations include mechanisms prosecutors commonly pursue in these cases—such as kickbacks and billing for medically unnecessary or improperly supported care. All charging details remain allegations until cases play out in court.
Whole-of-government enforcement alongside the criminal cases
DOJ also said the national announcement was paired with parallel administrative and civil actions:
- CMS: DOJ said CMS actions included suspending 1,079 providers and revoking billing privileges for 1,403 providers.
- HHS-OIG: DOJ said there were 48 Civil Monetary Payment settlements totaling over $73 million, over 1,400 provider exclusions, and 25 HHS-OIG actions under the Civil Monetary Penalties Law seeking more than $10 billion in payments to the Medicare Trust Fund.
- DEA: DOJ said DEA has opened 928 administrative cases seeking revocation of authority to handle and/or prescribe controlled substances, starting from October 1, 2025.
In practical terms, criminal charges and these administrative actions can move on different timelines—and administrative outcomes can affect whether providers can bill and handle controlled substances while matters proceed.
One DOJ example of what “fraud” can look like
DOJ highlighted what it described as fraudulent wound-care schemes involving amniotic wound allografts. The announcement says charges were filed against 11 defendants (including a company executive and eight medical professionals) across six districts tied to alleged billions of dollars in claims for these products.
In DOJ’s account, from roughly December 2021 through June 2024, providers billed Medicare over $4 billion for allografts connected to the scheme, resulting in over $2 billion in payments. DOJ alleged the conduct was driven not by medical necessity but by a kickback scheme and misuse of the products, including, in DOJ’s description, applying allografts to certain wounds without coordination with treating physicians and in ways that allegedly exceeded what was needed.
Opioid-related allegations DOJ described
DOJ also included a section it labeled Illegal Opioid Distribution, saying 36 defendants (including 28 licensed medical professionals) were charged in connection with alleged diversion of prescription opioids and other controlled substances. DOJ alleged that some opioid-related conduct involved a voicemail refill line for Schedule II prescriptions, and that DOJ-connected allegations include patient overdoses and deaths in connection with those prescriptions.
Who could be affected
The announcement’s reach is national, but the immediate real-world impact typically lands on multiple groups at once:
- Patients and beneficiaries whose care and access to prescriptions may be affected by provider suspensions, exclusions, or controlled-substance authority actions.
- Clinics, facilities, and billing operations that DOJ says were subject to CMS suspensions or revocations.
- Medicare and Medicaid programs, where DOJ and HHS-OIG described efforts to recover and prevent payments tied to alleged misconduct.
What to watch next
Because DOJ’s announcement is a “takedown results” announcement—not an end point—what comes next will depend on each district case and administrative track. Residents should watch for:
- Case-level filings in federal court, including next procedural steps that follow initial charging.
- Plea and sentencing developments where prosecutors move beyond charges.
- Ongoing CMS/HHS-OIG/DEA administrative processes tied to suspensions, exclusions, and controlled-substance authority revocation proceedings.
Sources
- DOJ Office of Public Affairs — Press Release (June 23, 2026): National Health Care Fraud Takedown Results in 455 Defendants Charged in Connection with Over $6.5 Billion in Alleged Fraud
- HHS Office of Inspector General — 2026 National Health Care Fraud Takedown Enforcement Page
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.